Oncologists will be able to use Third Wave Technologies' Invader UGT1A1 molecular assay to select appropriate doses of Pfizer's chemotherapy drug Camptosar (irinotecan)for colorectal cancer, following 510(k) clearance Aug. 22
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Ellipsis said it will use its new funding to expand its AI-powered voice assistant Sage across health systems. Ellipsis is part of the global vocal biomarker market, which is expected to exceed $9bn by the end of 2033, according to a research market report.
Commissioner Martin Makary told staff that plans are being developed to centralize HR, IT, travel and other functions, which were heavily impacted by the 1 April reduction-in-force.
